A Biochemical Society Focused Meeting
Abstract deadline: 17 May 2019
Earlybird registration deadline: 17 May 2019
Registration is now open.
The PI 3-kinase (PI3K) pathway is an intracellular signalling pathway at the crossroads of cell signalling and vesicular traffic. The Biochemical Society last organised a meeting on this topic in 2006 and, since then, the PI3K field has massively expanded. After some challenging years in PI3K pathway drug development, good progress has recently been made, with three PI3K inhibitors now approved for oncology and several others in the registration pipeline.
This conference will focus on the biology and signalling of the class I isoforms of PI3K, their downstream targets such as Akt/PKB and the drugs that have been generated to interfere with their function in disease. The speaker programme will bring together researchers to bridge the gap between basic science and translation, as well as industry figures who will provide an update on their PI3K programmes, and clinicians to share their feedback from some of the clinical trials.
This exciting event aims to provide a forum to share the latest discoveries, expand on the understanding of the basic biology science and signalling and examine novel translational opportunities, including neuroprotection and the treatment of rare diseases driven by PI3K pathway deregulation.
Bart Vanhaesebroeck, UCL
Sabina Cosulich, AstraZeneca
Gus Amour, GSK
Alison Condliffe, University of Sheffield
Oral communication slots are available at this meeting. All attendees, particularly researchers in the early stages of their career, are invited to submit a poster abstract for consideration as an oral communication.
Student Bursaries are available for this meeting.
Not a member of the Biochemical Society? Join today and save up to £100 on your registration fee.